amgen news - Search News

Amgen says obesity drug caused up to 20% weight loss

Newsweek on MSN · 28m

Amgen Drug Delivers More Weight Loss Than Competitors

A new weight loss drug developed by Amgen may provide better results with fewer injections than current treatments such as Ozempic and Wegovy, according to the results of a recent trial. Trial participants who were obese or overweight lost an average of 20 percent of their body weight in 12 months without their weight loss plateauing,

MarketWatch on MSN · 7h

Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms

Amgen Inc.’s stock was down 7% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed up to 20% average weight loss at 52 weeks. Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year,

Amgen's weight-loss drug fails to impress in study; shares plunge

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.

Seeking Alpha10h

Amgen: Checks All The Wrong Boxes

In the case of Amgen (NASDAQ:AMGN), I can honestly say I knew very little about the stock beyond its name and sector for a ...

1h

Hold Rating on Amgen’s Maritide Amid Uncertainties in Efficacy and Tolerability

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Amgen (AMGN – Research Report). The associated price target ...

21h

Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Amgen's big reveal of obesity data falls a bit flat

William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...

1h

Amgen price target lowered to $330 from $360 at RBC Capital

RBC Capital analyst Gregory Renza lowered the firm’s price target on Amgen (AMGN) to $330 from $360 and keeps an Outperform rating on the ...

FierceBiotech1d

Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

20hon MSN

Wait for longer-term data with Amgen's GLP-1, says Piper Sandler's Christopher Raymond

Wait for longer-term data with Amgen's GLP-1, says Piper Sandler's Christopher Raymond ...

1h

Evan Seigerman Recommends Buy on Amgen Due to Promising MariTide Trial Results and Strategic Growth Moves

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report) and keeping the price target at $362.00.Don't ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results